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Introduction {#sec006}
============

Hypertension is highly prevalent worldwide especially in oldest-old. In primary care, general practitioners (GPs) are paramount to decide on optimal blood pressure goals. However how best to treat hypertension in oldest-old (80 years or older) patients, especially those who are frail, is still an open question \[[@pone.0236064.ref001]\]. This population group is rarely the subject of specific recommendations in currently available guidelines for treating hypertension.

Oldest-old patients are a rapidly increasing segment of the population, and GPs see more and more of them \[[@pone.0236064.ref002]\]. These patients are a heterogeneous group. Some are healthy, while others are frail and live with multiple complex medical conditions. Despite the increase, this population is widely excluded from clinical trials, particularly from hypertension trials \[[@pone.0236064.ref003]\]. Most studies apply in fact very strict criteria excluding patients with other diseases than the condition under study, which reduces the generalizability of the results \[[@pone.0236064.ref004]\]. This statement is especially relevant in a primary care setting where over two thirds of patients over 50 of age have more than one chronic disease \[[@pone.0236064.ref005]\].

Treating hypertension effectively decreases cardiovascular risk factors in the general population \[[@pone.0236064.ref006]\], but there are no reliable data whether it is also the best treatment-strategy in the oldest-old. Whilst some trials suggested that lowering blood pressure benefits this group \[[@pone.0236064.ref007]\], most of these trials included only fit members of that age group. Meanwhile observational studies reported that low systolic blood pressure was associated with an increase in all-cause mortality in the oldest-old \[[@pone.0236064.ref008]--[@pone.0236064.ref010]\].

Many different hypertension guidelines are available. GPs therefore have to choose between regional, national, continental or international recommendations. As illustration, a well-known European guideline is edited by the European Society of Cardiology (ESC) with already four updated versions, the current one published in 2018 \[[@pone.0236064.ref011]\]. The National Institute for Health and Care Excellence (NICE) also provides some national recommendations, which are popular among English GPs \[[@pone.0236064.ref012]\]. Another national guideline, developed by the Dutch College of GPs (NHG), is implemented in the Netherlands \[[@pone.0236064.ref013]\].

In this study we aim to assess if GPs used guidelines when deciding on how to treat hypertension in their oldest-old and frail patients, and if guideline-users decide differently from non-users.

Methods {#sec007}
=======

Design {#sec008}
------

We conducted a re-analysis of data from the cross-sectional case-vignettes study called '*A*ntihypertensive *T*rea*T*m*ENT I*n *V*ery *E*lderly' (ATTENTIVE) \[[@pone.0236064.ref014]\].

Setting {#sec009}
-------

We organized a network of 'national coordinators' (mostly one per country) through national and European GP's organizations. The role of the national coordinator was to seek ethical approval for the local data collection (if applicable), supervise translation of the survey and send out the survey and reminders to their GP network(s). The surveys were distributed from spring to summer 2016. The detailed design of the ATTENTIVE Study has been described previously \[[@pone.0236064.ref014],[@pone.0236064.ref015]\].

Ethical considerations {#sec010}
----------------------

Our study accords with the ethical principles of the Declaration of Helsinki \[[@pone.0236064.ref016]\]. The GPs' responses to the survey served as their informed consent. Because the survey was anonymous, there was no need to seek ethical approval in most countries. The ethics committees of Brazil and Switzerland specifically waived the requirement. We sought and obtained approval from the ethics committee of Auckland University in New Zealand.

Participants {#sec011}
------------

The only inclusion criteria to participate in the ATTENTIVE study, was to be currently active as a GP. We excluded GPs who were not practicing anymore. GPs were recruited by email and answered the survey without any incentive.

Procedures {#sec012}
----------

The questionnaire was published online in English and 21 other languages corresponding to the participating countries on SurveyMonkey® ([www.surveymonkey.com](http://www.surveymonkey.com/), Palo Alto, CA, USA). Content validity of the translations where checked by the national coordinators who were all fluent in English. In Ukraine, where web access was limited, a paper version was administered. The first set of survey questions determined GP -specific characteristics (sex, years of experience as a GP, estimation of prevalence of oldest-old patients and location of their practice). Then, GPs were asked if they used hypertension guidelines to decide how to treat the oldest-old, and which guidelines they used. We defined the first guideline they mentioned as the most important. We analyzed all the documented guidelines and we categorized them. When local guidelines referred to another guideline (e.g., from the ESC), we counted it as the second guideline. If GPs listed something other than a guideline, we classified it under "Others" ([S1 Appendix](#pone.0236064.s001){ref-type="supplementary-material"}).

The complete survey described eight case-vignettes where oldest-old male or female patients presented for a routine control (Additional file 1 in \[[@pone.0236064.ref014]\]). These patients had no symptoms suggesting hypertension and took no antihypertensive medication. The vignettes differentiated by the following variables: systolic blood pressure (SBP; options: 140 or 160mmHg), presence or absence of history of cardiovascular disease like myocardial infarction or stroke, and presence or absence of frailty. In each case, GPs were asked to decide whether they would start antihypertensive treatment. In our study, we analysed data from four of the eight case-vignettes that applied to frail oldest-old patients. We defined frailty when at least two of the following Fried's criteria were present: unintentional weight loss, muscle weakness, exhaustion, slow gait speed and low level of activity \[[@pone.0236064.ref017]\].

Statistical analysis {#sec013}
--------------------

We used descriptive statistics to compare baseline characteristics in the whole sample and stratified by guideline use (rather yes and yes = yes; neutral, rather no and no = no). We used a Chi2-test to assess categorical data and a complete case analysis to handle missing data. To assess how GPs varied in their use of guidelines when they treated hypertension in the oldest-old, we calculated the crude proportions and 95% confidence intervals (CI) per country. To assess the role that guidelines played in GPs' decisions, we used a mixed-effects Poisson model to calculate percentages and 95% CIs of GPs who decided to treat hypertension across the four case-vignettes. We adjusted the model for sex and years of experience and stratified it by guideline use. We used a mixed-effects model to account for a clustering effect within each country and used the same model to stratify the guidelines that GPs said they followed further. To lower the risk of selection bias in countries with a low response rate, we performed a sensitivity analysis restricted to countries where \>60% of GPs responded. Based on the distribution of guidelines GPs mentioned ([S1 Appendix](#pone.0236064.s001){ref-type="supplementary-material"}), we made a 5-category group that included the three most frequently mentioned guidelines (ESC, NICE, NHG, and every other guideline), and GPs who said they did not use guidelines (reference group). We considered a two-sided p-value of 0.05 to be statistically significant. STATA 15.1 (StataCorp, College Station, TX, USA) was used for all analyses.

Results {#sec014}
=======

We received responses from the 29 following countries: Switzerland, France, Germany, Luxembourg, Netherlands, Italy, Spain, Portugal, United Kingdom, Ireland, Austria, Denmark, Norway, Sweden, Finland, Greece, Slovenia, Latvia, Czech Republic, Hungary, Macedonia, Turkey, Ukraine, Poland, Romania, Bosnia Herzegovina, Brazil, Israel and New Zealand. After excluding 42 GPs who were no longer practicing, we included 2,543 GPs. The median response rate across countries was 26% (Inter Quartile Range 10--62%). 52.7% of the participating GPs were women. About one third of GPs (37.6%) had more than 20 years of experience. The self-reported prevalence of oldest-old in most GP practices ranged from 10% to 20%. Only 7.2% listed a prevalence higher than 30%. Half of the GPs practiced in a city while the two remaining quarters of GPs were located in suburban and rural area.

About 60% of GPs mentioned using guidelines when they treat hypertension in the oldest-old. Female and GPs with under 20 years of experience were more likely to use guidelines while GPs with the most experience (more than 20 years) reported using them less frequently. We found that reported prevalence of seeing oldest-old patients and the location of GPs' practices were not significantly associated with guideline use ([Table 1](#pone.0236064.t001){ref-type="table"}).

10.1371/journal.pone.0236064.t001

###### Baseline characteristics of general practitioners by guideline use during decision-making on treatment of hypertension in oldest old patients (n = 2,543).

![](pone.0236064.t001){#pone.0236064.t001g}

                                                                 Guideline use                
  ----------------------------------------------- -------------- --------------- ------------ ---------
  **Sex, n (%)**                                                                              
  Female                                          1,341 (52.7)   823 (54.5)      518 (50.2)   0.031
  **Clinical Experience, n (%)**                                                              
  \<5 years                                       471 (18.5)     314 (20.8)      157 (15.2)   \<0.001
  5--10 years                                     445 (17.5)     274 (18.1)      171 (16.5)   
  11--15 years                                    341 (13.4)     203 (13.5)      138 (13.4)   
  16--20 years                                    328 (12.9)     204 (13.5)      124 (12.0)   
  \>20 years                                      956 (37.6)     514 (34.1)      442 (42.8)   
  **Estimated prevalence of oldest-old, n (%)**                                               
  \<10%                                           851 (38.7)     591 (39.2)      260 (37.7)   0.145
  10--20%                                         865 (39.4)     576 (38.2)      289 (41.9)   
  21--30%                                         323 (14.7)     222 (14.7)      101 (14.7)   
  \>30%                                           159 (7.2)      120 (8.0)       39 (5.7)     
  **Location of the practice, n (%)**                                                         
  City                                            1292 (50.8)    793 (52.5)      499 (48.3)   0.078
  Suburban                                        599 (23.6)     336 (22.3)      263 (25.5)   
  Rural                                           651 (25.6)     380 (25.2)      271 (26.2)   

^a^ Chi-square test for categorical variables

We found a large variation in guideline use across countries, ranging from less than 25% in New Zealand to almost 90% in Ukraine ([Fig 1](#pone.0236064.g001){ref-type="fig"}, [S2 Appendix](#pone.0236064.s002){ref-type="supplementary-material"}). Over 80% of GPs in Brazil, Greece, Czech Republic, Macedonia, Slovenia, Romania and Ukraine reported using guidelines. Across all countries, 20 different guidelines were mentioned. 95% of guideline users mentioned at least one of the guidelines listed in [S1 Appendix](#pone.0236064.s001){ref-type="supplementary-material"}. Inherent to the distribution of number of participants per country, the most commonly mentioned guidelines were the NICE, ESC and NHG (the 'Dutch College of GPs') guidelines. They resulted in 60% of mentions. Treatment recommendations of these three guidelines are summarized in [S3 Appendix](#pone.0236064.s003){ref-type="supplementary-material"}. There were no specific treatment recommendations for frail oldest-old patients in these three guidelines regardless of the absence or presence of cardiovascular disease history. The decision was left to the treating physician.

![Crude percentages of general practitioners using guidelines by country when treating hypertension in frail oldest-old.](pone.0236064.g001){#pone.0236064.g001}

[Table 2](#pone.0236064.t002){ref-type="table"} stratifies the treatment recommendation to start antihypertensive medication on guideline users and non-users. We found that proportions advising to start treatment differed by the case characteristics. However, GPs made similar decisions about treating or not treating hypertension in frail oldest-old patients, whether they reported to use guidelines or not. The exception in the case of a patient without history of CVD and SBP 140mmHg, in which there was an evidence for more treatment in guideline users (16% of guideline users decided to treat, 95%CI 11%-24%) compared to non-users (12% of non-users decided to treat, 95%CI 7--18%, p = 0.015). However, when restricting GPs to only those countries with a higher than 60% response rate (n = 8 countries; 676 participants), this difference was no longer statistically significant: guideline users and non-users (19%, 95%CI 9%-40%, p = 0.28).

10.1371/journal.pone.0236064.t002

###### Proportions of general practitioners starting antihypertensive treatment in frail oldest-old stratified by history of cardiovascular disease, systolic blood pressure and use of guidelines.

![](pone.0236064.t002){#pone.0236064.t002g}

                    Patients with no history of cardiovascular disease   Patients with history of cardiovascular disease                   
  ----------------- ---------------------------------------------------- ------------------------------------------------- --------------- ---------------
  **Guideline**                                                                                                                            
  **- Users**       16% (11%-24%)                                        80% (69%-94%)                                     37% (28%-49%)   86% (77%-97%)
  **- Non-users**   12% (7%-18%)                                         73% (61%-88%)                                     31% (23%-43%)   80% (69%-92%)
  ** P-value**      0.015                                                0.13                                              0.09            0.12

Proportions and p-values comparing users and non-users from mixed Poisson regression models adjusted for GP sex, years of experience and country

In [Fig 2](#pone.0236064.g002){ref-type="fig"}, we further stratified GP treatment decisions by the three most often mentioned guidelines, other guidelines, and no guidelines. GPs in all categories made similar decisions for each case-vignette, no matter which guidelines was applied (or no guideline applied). However, there seems to be a trend that NHG-users were less likely to treat patients without history of CVD when SBP was 160 mmHg, but this finding was not statistically significant.

![General practitioners deciding to start antihypertensives in frail oldest-old stratified by type of guidelines used and no guideline used.](pone.0236064.g002){#pone.0236064.g002}

Discussion {#sec015}
==========

Our study of more than 2,500 GPs from 29 countries found that about 60% of GPs reported to use guidelines when treating hypertension in frail oldest-old. These proportions varied largely between countries, from less than 25% in New Zealand to almost 90% in Ukraine. Less experienced GPs and female GPs were more likely to use guidelines. However, GPs from all countries overall seemed to make similar treatment decisions when confronted with cases of frail oldest-old patients, whether or not they used guidelines, and regardless which guidelines they used.

Clinical context and comparison with existing literature {#sec016}
--------------------------------------------------------

While guideline use might have no major effect on treatment decisions in frail oldest-old, frailty, systolic blood pressure and history of cardiovascular disease seemed to have an influence \[[@pone.0236064.ref014]\]. In addition, country-specific factors such as cardiovascular burden and life expectancy are associated with the decisions when managing hypertension in this age group \[[@pone.0236064.ref015]\].

An explanation of why no association between guideline use and treatment decisions was found could be the absence of specific and clear recommendations in most current guidelines for this population group. As shown in S3 Appendix the decision to treat frail oldest-old patients with systolic blood pressure of 160 mmHg was left to the treating physician in the three most frequently mentioned guidelines at the time of the survey. Despite the lack of specific recommendation, the problematics of frail and older patients are discussed in these three guidelines. However no major changes were made concerning frail oldest-old in the new versions of ESC, NICE and NHG guidelines since 2016 and there are still no specific recommendations for this patient group \[[@pone.0236064.ref011]--[@pone.0236064.ref013]\]. Therefore, GPs are left to make treatment decisions based on other factors such as patient characteristics and personal judgement rather than on guidelines \[[@pone.0236064.ref018]\]. We assume GPs would use more guidelines if they were more applicable to the types of patients they treat. Moreover, the literature outlines patient safety to be more important than adherence to guidelines \[[@pone.0236064.ref019]\].

Some guidelines, however, pay a particular attention to oldest-old and frail patients e.g. the NHG guideline \[[@pone.0236064.ref013]\]. This work was an initiative of Dutch GPs involving all healthcare professionals in cardiovascular disease prevention in a multidisciplinary workgroup. In our study, in the case of primary prevention and SBP of 160mmHg, we could see that NHG-users seemed to treat less, however, the confidence interval overlapped with the proportions of GPs that adhered to other or no guidelines. This observation may imply that guidelines could influence GPs' treatments decision in frail oldest-old if specific recommendations are provided.

In the present study, we found that female doctors were more likely to use hypertension guidelines when treating frail oldest-old patients. This is in line with findings from other studies that described higher adherence to clinical guidelines by female physicians when treating other chronic conditions such as diabetes \[[@pone.0236064.ref020]\].

Limitations and strengths {#sec017}
-------------------------

This study has several limitations but also strengths. First, we did not compare GPs' treatment decisions in oldest-old patients with and without frailty, which is why we cannot comment on the effect of guidelines on GPs' treatment decisions in non-frail oldest-old adults. Second, asking GPs what they would do is not the same as measuring what they really do. However, the use of a case-vignette study allows comparing decisions in different countries while still having a standardized situation, which can be seen as a strength when comparing across countries. We believe anonymity also lowered social desirability bias risk. Third, our median response rate of 26% is quite modest, but studies with GPs often have such a moderate response rate. In order to minimize and control for selection bias we mitigated that risk by running a sensitivity analysis of countries where the response rate was higher (more than 60%). We further acknowledge that due to different numbers of respondents per country the list of most used guidelines is skewed to overestimate responses from countries with many participants. However, we focused on the variety by including almost 30 countries, with some being able to recruit more and other being able to recruit less GPs. This approach also let us include responses from countries sometimes under-represented in research. Moreover, it is the first study to our knowledge to investigate guideline use and treatment decisions in frail and oldest-old with hypertension through standardized case-vignettes.

Implications for research and/or practice {#sec018}
-----------------------------------------

Until future primary care trials with oldest-old and frail patients will assess the benefits and risks of hypertension treatment in this population group, our study suggests that due to the remaining clinical dilemma, some GPs will choose not to follow any guidelines at all. One possible explanation may be the absence of specific recommendations for a highly heterogenous group: the oldest-old patients. Second, the absence of agreement between the various recommendations was found to be associated with a large variation in how GPs apply preventive measures \[[@pone.0236064.ref021]\]. The development of future guidelines should ideally address these differences and enhance the consensus with guidelines approved by all stakeholders. Further, guideline committees would benefit from sustained efforts in consulting patients as well as GPs in order to be able to better identify the needs of this patient group. Such an approach would decrease the potential of conflicting interests compared to guidelines written by professional societies and might lower the risk of overtreatment \[[@pone.0236064.ref022],[@pone.0236064.ref023]\]. A good illustration of this kind of recommendations is the guideline from the NICE about the management of multimorbid patients published in 2016 \[[@pone.0236064.ref024]\]. The present guidelines with an often complex and ambiguous text might also be an important barrier to GPs' adoption of recommendations \[[@pone.0236064.ref025]\].

Future efforts should be made by including oldest-old patients into clinical studies and GPs in guideline committees to develop more specific guidelines with recommendations for oldest-old and frail patients with hypertension.

Conclusions {#sec019}
===========

Most GPs reported to be using guidelines when treating hypertension in oldest-old patients, but there was variation across countries and a plurality of different guidelines were mentioned. Nevertheless, guideline-users made similar treatment decisions compared to non-users. This suggests that the individual patient characteristics have a higher impact on GPs' treatment decisions than guidelines, which still fail to provide guidance concerning the optimal treatment in oldest-old and frail patients.

Supporting information {#sec020}
======================

###### Names of the most frequent guidelines mentioned.

(PDF)
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Click here for additional data file.

###### Percentage of guideline use per country.

(PDF)
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Click here for additional data file.

###### Hypertension treatment recommendations for frail oldest-old and oldest-old in the three most mentioned guidelines.
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1st Reviewer comments:

1\. In this study, the authors analyzed the data of the worldwide survey from GPs and investigated whether guideline use influence the treatment choice for hypertensive oldest-old with frailty defined by Fried criteria. They found that GPs who used guidelines are less experienced and more female, but there was no specific tendency with respect to guideline use to treat frail oldest-old.

Major points

The authors speculate that guideline use had no effect on treatment decisions in frail oldest-old, because of the absence of specific and clear recommendations in most current guidelines for this population group. However, this speculation could suffer from the absence of positive control group in which guideline use significantly affects the treatment. Given that their questionnaires were limited to the treatment of the oldest-old, it might be helpful to assess the treatment of oldest-old with non-frailty and compare the results in those with frailty. The hypothesis can be strengthened, if there is any difference in treatment tendency between the guideline users and non-users in non-frailty patients.

Response: We thank the reviewer for pointing out this important aspect. We agree that the absence of positive control group with oldest old patients without frailty is a limitation of our study. We therefore clarified this point in the section "Limitations and strengths" on page 12. We consciously chose to focus on frail oldest-old because of two main reasons. First, recommendations for this specific population are missing from most hypertension guidelines. This fact is described in the literature \[references 1 and 2 below\] as well as in guidelines. For example, these two citations from the hypertension guideline of the European Society of cardiology (ESC) state that "all of the above recommendations relate to relatively fit and independent older patients, because physically and mentally frail and institutionalized patients have been excluded in most RCTs of patients with hypertension" and "In some patients, best achievable BP may be higher than the recommended target" \[3\]. Secondly, this population group is especially at risk for negative consequences of too aggressive blood pressure treatment while oldest-old without frailty may have a greater tolerance \[4\].

2.The reviewer recommends to show the table to summarize the recommendation of treatment in oldest-old with or without frailty among clinical guidelines. If there is no specific recommendation to these populations in guidelines, the recommendation to treatment in older patients can be alternatively shown.

Response: We appreciate this suggestion and we added a new table to summarize the main recommendations in the appendix S3. We chose to present the recommendations for frail oldest-old of the three most mentioned guidelines, which were effective at the time of our study in 2016. We hope this table will help to get an overview of the contents of the guidelines. We also provided the information on guidelines changes since then (refer to the Discussion Section on page 11).

2nd Reviewers comments:

1\. Dear Authors,

Thank you for submitting the research. The topic is important and the results are relevant.

Though the manuscript is written in a sufficient way, please find some minor suggestions for improvement:

\- Abstract section Design/Section could be supplemented with some setting description;

Response: We completed this section with the following sentence: "Cross-sectional study among currently active GPs from 29 countries using a case-vignettes survey."

2\. Abstract Methods section lists the countries that participated in the study: Europe, Brazil, Israel and New Zealand. But the first is continent and the others are countries. I suggest writing \"European countries\". By the way, I\'d see it rational to mention the countries participating in the research

Response: We thank the reviewer for this comment and adapted in the abstract as follows: "GPs from 26 European countries and from Brazil, Israel and New Zealand were invited". We listed all the countries under "Results" on page 8.

3\. I suggest adding some explanation about the guidelines in the Introduction section. Are they national, international, similar in some countries, etc. Are they available in all countries?

Response: This comment is relevant and we agree that some more explanations about the different guidelines would help the reader. We chose to integrate a short description of the guidelines in the "Introduction" on page 5.

4\. In the Setting section you mention EGPRN as an example. I suggest to include some other as well or not mention organization at all.

Response: We agree with this remark and removed the name of this organization.

5\. Please describe how the GPs were selected to involve as the participants. Was the criterion(s) similar for all the countries or local coordinators decided? How their contacts for sending the questionnaire link were gathered?

Response: We are happy to clarify this point. The GPs were contacted by a national coordinator, which we collaborate with through national and European organizations, as explained in the section "Methods" from page 5 to 7. To clarify the inclusion criteria, we adapted the subsection "Participants" on page 6 as follow: "The only inclusion criteria to participate in the ATTENTIVE study, was to be currently active as a GP". National coordinators sent the link of the survey per e-Mail, except in Ukraine where a paper version was distributed as detailed on page 6 and 7. More explanations on the data collection can be found in the original publications of the ATTENTIVE study \[5,6\].

6\. I suggest adding some statistics on GPs distribution among the countries. Maybe adding (if it\'s available) urban/rural distribution. I believe it would be valuable to present some more correlations between demographics and using the guidelines. Of course, if it\'s available.

We thank the reviewer for this relevant comment. Data about the location of GP's practices were collected in the ATTENTIVE study. We therefore completed our sections "Methods" and "Results" as well as Table 1. We found no association between GPs' geographical location and guideline use.
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